Patent · US Active

RNA transcription vector and uses thereof

US10159755B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignee

VRIJE UNIVERSITEIT BRUSSEL · BE

Inventors

Carlo Heirman · Dendermonde, BE
Kristiaan Thielemans · Ekeren, BE

Key dates

Filing date	Nov 12, 2014
Grant date	Dec 25, 2018
Priority date	—
Expiry date	Nov 12, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2840/105
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the “Expression and Nuclear Retention Element” (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.